Refine
Document Type
- Article (4)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Keywords
- Hofmannsthal, Hugo von (2)
- Acute HIV infection (1)
- Antisemitismus (1)
- Brief (1)
- HIV (1)
- Nestroy, Johann (1)
- Pannwitz, Rudolf (1)
- Raimund, Ferdinand (1)
- Rapid diagnostic test (1)
- Rezeption (1)
Institute
- Medizin (2)
Background & Aim: The resistance profile of anti-hepatitis C virus (HCV) agents used in combination is important to guide optimal treatment regimens. We evaluated baseline and treatment-emergent NS3/4A and NS5B amino-acid variants among HCV genotype (GT)-1a and -1b-infected patients treated with faldaprevir (HCV protease inhibitor), deleobuvir (HCV polymerase non-nucleoside inhibitor), and ribavirin in multiple clinical studies.
Methods: HCV NS3/4A and NS5B population sequencing (Sanger method) was performed on all baseline plasma samples (n = 1425 NS3; n = 1556 NS5B) and on post-baseline plasma samples from patients with virologic failure (n = 113 GT-1a; n = 221 GT-1b). Persistence and time to loss of resistance-associated variants (RAVs) was estimated using Kaplan–Meier analysis.
Results: Faldaprevir RAVs (NS3 R155 and D168) and deleobuvir RAVs (NS5B 495 and 496) were rare (<1%) at baseline. Virologic response to faldaprevir/deleobuvir/ribavirin was not compromised by common baseline NS3 polymorphisms (e.g. Q80K in 17.5% of GT-1a) or by NS5B A421V, present in 20% of GT-1a. In GT-1b, alanine at NS5B codon 499 (present in 15% of baseline sequences) was associated with reduced response. Treatment-emergent RAVs consolidated previous findings: NS3 R155 and D168 were key faldaprevir RAVs; NS5B A421 and P495 were key deleobuvir RAVs. Among on-treatment virologic breakthroughs, RAVs emerged in both NS3 and NS5B (>90%). Virologic relapse was associated with RAVs in both NS3 and NS5B (53% GT-1b; 52% GT-1b); some virologic relapses had NS3 RAVs only (47% GT-1a; 17% GT-1b). Median time to loss of GT-1b NS5B P495 RAVs post-treatment (5 months) was less than that of GT-1b NS3 D168 (8.5 months) and GT-1a R155 RAVs (11.5 months).
Conclusion: Faldaprevir and deleobuvir RAVs are more prevalent among virologic failures than at baseline. Treatment response was not compromised by common NS3 polymorphisms; however, alanine at NS5B amino acid 499 at baseline (wild-type in GT-1a, polymorphism in GT-1b) may reduce response to this deleobuvir-based regimen.
Über Assimilation, deutsch-jüdische "Symbiose" und politischen Antisemitismus in Wien und Österreich während der k.u.k. Monarchie und der Ersten Republik gibt es umfangreiches Material, das Interessierten sowohl mentalitätsgeschichtlich als auch soziologisch und statistisch über die damaligen Verhältnisse gründlich Auskunft erteilt. Und seit Carl Schorskes vieldiskutierter Darstellung des "Fin de siècle" ist auch Hofmannsthal mehrfach in diese Untersuchungen einbezogen worden, eindrücklich von Jens Rieckmann. Debattiert wurde einerseits, ob – und in welcher Form – Hofmannsthals jüdisches Erbe in seinem Werk erkennbar sei, aber ebenso, ob er, insbesondere mit seiner heftigen Reaktion auf Dichtungen von Schnitzler und Beer-Hofmann, dabei einer Art von "jüdischem Selbsthaß" erlegen sei, der abgelehnte Ichanteile nach außen und auf andere projizierte. Und mehrfach besprochen wurde auch, wie abweisend Hofmannsthal in den 20er Jahren auf Versuche antwortete, ihn - durchaus lobend - in Publikationen zusammen mit jüdischen Autoren darzustellen.
Hofmannsthal war auch als Philologe Dichter. Das zeichnet seine literaturkritischen Arbeiten aus, macht sie aber einzigartig subjektiv. Zudem ist die Denk- und Empfindungsweise der Epoche in diesen Texten deutlich präsent. Das gilt für das Meiste, was er an Würdigungen, Einleitungen und Reden schrieb. Es wird uns hier in seinen Urteilen über Nestroy und Raimund beschäftigen.
In resource-limited or point-of-care settings, rapid diagnostic tests (RDTs), that aim to simultaneously detect HIV antibodies and p24 capsid (p24CA) antigen with high sensitivity, can pose important alternatives to screen for early infections. We evaluated the performance of the antibody and antigen components of the old and novel version of the Determine™ HIV-1/2 Ag/Ab Combo RDTs in parallel to quantifications in a fourth-generation antigen/antibody immunoassay (4G-EIA), p24CA antigen immunoassay (p24CA-EIA), immunoblots, and nucleic acid quantification. We included plasma samples of acute, treatment-naïve HIV-1 infections (Fiebig stages I–VI, subtypes A1, B, C, F, CRF02_AG, CRF02_AE, URF) or chronic HIV-1 and HIV-2 infections. The tests’ antigen component was evaluated also for a panel of subtype B HIV-1 transmitted/founder (T/F) viruses, HIV-2 strains and HIV-2 primary isolates. Furthermore, we assessed the analytical sensitivity of the RDTs to detect p24CA using a highly purified HIV-1NL4-3 p24CA standard. We found that 77% of plasma samples from acutely infected, immunoblot-negative HIV-1 patients in Fiebig stages II–III were identified by the new RDT, while only 25% scored positive in the old RDT. Both RDTs reacted to all samples from chronically HIV-1-infected and acutely HIV-1-infected patients with positive immunoblots. All specimens from chronically infected HIV-2 patients scored positive in the new RDT. Of note, the sensitivity of the RDTs to detect recombinant p24CA from a subtype B virus ranged between 50 and 200 pg/mL, mirrored also by the detection of HIV-1 T/F viruses only at antigen concentrations tenfold higher than suggested by the manufacturer. The RTD failed to recognize any of the HIV-2 viruses tested. Our results indicate that the new version of the Determine™ HIV-1/2 Ag/Ab Combo displays an increased sensitivity to detect HIV-1 p24CA-positive, immunoblot-negative plasma samples compared to the precursor version. The sensitivity of 4G-EIA and p24CA-EIA to detect the major structural HIV antigen, and thus to diagnose acute infections prior to seroconversion, is still superior.